Hot Investor Mandate: USA-Based VC Invests Up to $25M in Therapeutics & Platform Technologies From Pre-Clinical to Phase 3 in All Indication Areas

1 Sep

A venture capital firm founded in the USA closed its first fund in 2017 and is actively seeking new investment opportunities. The fund will make 15-20 investments in total with no set number of investments per year. The firm will be actively involved in their portfolio companies and will invest up to $25 million over the life of each portfolio company. Initial check sizes will depend on the company’s stage of development and their needs prior to investment. The firm will invest in North American or European companies.

The firm is focused solely on therapeutics and therapeutic platforms. The fund will invest at any stage of development from preclinical / discovery stage through Phase 3 clinical, and will invest in all therapeutic areas.

The firm can work with companies at all stages of their evolution. The firm’s team has the capability and experience to build companies from the ground up, however generally gets involved with at least the beginnings of a management team in place. The firm can both lead and co-invest along syndicates and will generally seek board representation in portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: